BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August 10, 2017, BioLife Solutions, Inc. (the “Company”) issued a press release announcing the financial results and operational highlights for the second quarter ended June, 30 2017. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| ExhibitNo. | Description |
| 99.1 | Press release, dated August 10, 2017 |
BIOLIFE SOLUTIONS INC ExhibitEX-99.1 2 v472868_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioLife Solutions Announces Second Quarter 2017 Financial Results 29% Year Over Year Revenue Growth Conference Call and Webcast Today at 4:30 PM Eastern Time BOTHELL,…To view the full exhibit click here
About BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS)
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.
